Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.18M Buy
3,259
+1,377
+73% +$471K 0.47% 52
2026
Q1
$662K Sell
1,882
-203
-10% -$72.4K 0.29% 64
2025
Q4
$682K Buy
+2,085
New +$661K 0.27% 73

Other funds holding AMGN

Cane Capital Partners's AMGN Position: Q2 2026 in Review

Cane Capital Partners increased its Amgen (AMGN) stake by 73% in Q2 2026, buying an estimated $471K and bringing the position to 3,259 shares worth $1.18M. The position accounts for 0.47% of the portfolio, ranked #52.

Cane Capital Partners first reported a position in AMGN in Q4 2025 and has held it in 3 quarters since. 3,133 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Cane Capital Partners held 3,259 shares of Amgen worth $1.18M as of Q2 2026.
  • Cane Capital Partners bought 1,377 Amgen shares in Q2 2026, an estimated $471K.
  • Amgen made up 0.47% of Cane Capital Partners's portfolio in Q2 2026, its #52 holding.
  • Cane Capital Partners first reported a position in Amgen in Q4 2025 and has held it in 3 quarters since.
  • 3,133 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Cane Capital Partners's 13F filing for Q2 2026, filed 5 Aug 2026.